Biotech Values

[genisi]

CRME- safety concerns for IV vernakalant

>Do you think there is enough room to speculate the drug may not have been related in that case as well?<

The patient in the IV program, who died of fatal MI, became hypotensive in response to vernakalant, which likely contributed to his death. The other death in the IV program was in a patient that received ibutilide, which is known to be associated with high rates of ventricular fibrillation.

Regarding other drugs, I don't know for sure. Will search when I'll have the time.